RIPK1 and Stroke: Similarly, yet better characterized, necroptosis has been shown to be a promising drug target in PD, AD, and stroke [58], with RIPK1 inhibition alleviating brain damage in models of MS [59], AD [60, 61], PD [62, 63], and stroke [64, 65].